NRx Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan C. Javitt
- Full Time Employees
- 29
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1201 Orange Street Wilmington DE United States of America 19801
- IPO Date
- Dec 4, 2017
- CIK
- 0001719406
- Website
- nrxpharma.com
- Similar Companies
- Business
- NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and addressing unmet medical needs in neurology and infectious diseases. The company offers a pipeline of product candidates including NRX-101 for bipolar depression and akathisia; NRX-100 for catatonia and bipolar depression; NRX-102 for bipolar depression with mixed features and agitation; and ZYESAMI (aviptadil) for critical care indications such as COVID-19-related acute lung injury and sarcoidosis. These therapies target severe psychiatric conditions, central nervous system diseases, and respiratory distress, with clinical trials emphasizing rapid symptom relief and reduced reliance on sedatives or antipsychotics. Founded in 2011 and headquartered in Radnor, Pennsylvania, NRx operates primarily in the United States with global clinical trial collaborations. Recent developments include positive Phase 3 trial data for NRX-101 in bipolar depression with suicidality, submission of New Drug Applications to the FDA, and a strategic licensing agreement for NRX-102 in the European market. In 2025, the company announced expansions in its pipeline through partnerships for combination therapies and secured additional funding via equity offerings to support ongoing trials and regulatory milestones.
Company News
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics